Zhao Yuanyuan, Tan Fangqin, Zhao Jiajia, Zhou Shuchang, Luo Yao, Gong Chen
Department of Oncology Department of Radiology Institute of Organ Transplantation Tongji Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan China.
Key Laboratory of Organ Transplantation Ministry of Education NHC Key Laboratory of Organ Transplantation Key Laboratory of Organ Transplantation Chinese Academy of Medical Sciences Organ Transplantation Clinical Medical Research Center of Hubei Province Wuhan Wuhan China.
MedComm (2020). 2025 May 15;6(6):e70202. doi: 10.1002/mco2.70202. eCollection 2025 Jun.
Cancer is a major public health, societal, and economic challenge worldwide. According to , it is estimated that by 2050, there will be 35 million new cancer cases globally. Although patient survival rates have improved through various therapeutic approaches, including surgery, chemotherapy, and radiotherapy, treatment efficacy remains limited once tumor metastasis occurs. Among various cancer treatment strategies, radiotherapy plays a crucial role. Along with surgery and chemotherapy, radiotherapy is a cost-effective single-modality treatment, accounting for approximately 5% of total cancer care costs. The use of radiosensitizing agents such as histone deacetylase inhibitors, 2-deoxy-d-glucose, enterolactone, and squalene epoxidase can enhance radiotherapy effectiveness. Recent radiosensitization methods involve physical stimuli and chemical radiosensitizers. However, improving their efficacy, durability, and overcoming radioresistance remain significant challenges. This review first introduces current applications of radiotherapy in cancer treatment, the molecular mechanisms underlying its anticancer effects, and its side effects. Second, it discusses the main types of radiosensitizers, their latest applications, and recent challenges in cancer treatment. Finally, it emphasizes on clinical trials of radiosensitizing agents and explores potential biomarkers for radiotherapy response in cancer. Multifunctional nanoparticles have shown greater clinical applicability than single-functional nanoparticles. Future research will focus on enhancing the drug-carrying capacity of nanomaterials to further improve radiotherapy outcomes.
癌症是全球主要的公共卫生、社会和经济挑战。据估计,到2050年,全球将有3500万新增癌症病例。尽管通过手术、化疗和放疗等各种治疗方法,患者生存率有所提高,但一旦肿瘤发生转移,治疗效果仍然有限。在各种癌症治疗策略中,放疗起着至关重要的作用。与手术和化疗一样,放疗是一种具有成本效益的单一治疗方式,约占癌症治疗总费用的5%。使用组蛋白去乙酰化酶抑制剂、2-脱氧-D-葡萄糖、肠内酯和角鲨烯环氧酶等放射增敏剂可以提高放疗效果。最近的放射增敏方法涉及物理刺激和化学放射增敏剂。然而,提高它们的疗效、耐久性以及克服放射抗性仍然是重大挑战。本综述首先介绍放疗在癌症治疗中的当前应用、其抗癌作用的分子机制及其副作用。其次,讨论放射增敏剂的主要类型、它们的最新应用以及癌症治疗中的最新挑战。最后,强调放射增敏剂的临床试验,并探索癌症放疗反应的潜在生物标志物。多功能纳米颗粒已显示出比单功能纳米颗粒更大的临床适用性。未来的研究将集中在提高纳米材料的载药能力,以进一步改善放疗效果。
Crit Rev Oncol Hematol. 2022-1
Pharmaceutics. 2021-10-21
Macromol Rapid Commun. 2022-9
Int J Nanomedicine. 2020-11-24
Mater Horiz. 2025-6-3
Front Oncol. 2022-2-7
MedComm (2020). 2024-11-28
Mol Biol Rep. 2024-11-13
Transl Cancer Res. 2024-7-31
Breast Cancer (Dove Med Press). 2024-7-15
Breast Cancer (Dove Med Press). 2024-7-16
Research (Wash D C). 2024-7-23